← Back to Search

Virus Therapy

Cohort 1 (first 60 subjects) PHV02 high dose for Nipah Virus

Phase 1
Recruiting
Research Sponsored by Public Health Vaccines LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Healthy, adult, male or non-pregnant, non-lactating females
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, 29, 57
Awards & highlights

Study Summary

This trial is testing a new vaccine called PHV02 in healthy adults. The trial wants to find out what doses of PHV02 are safe and well-tolerated, and what the immune response

Who is the study for?
This trial is for healthy adults who can participate in a study testing the safety of a Nipah virus vaccine called PHV02. Participants will receive two doses one month apart and be monitored over several months. Specific eligibility criteria are not provided, but typically include being within a certain age range and having no underlying health conditions.Check my eligibility
What is being tested?
The trial is examining the safety and immune response to different doses of the PHV02 vaccine against Nipah virus in healthy adults. It involves two intramuscular injections given one month apart, with follow-up for about half a year to measure antibody levels.See study design
What are the potential side effects?
While specific side effects are not listed, common reactions to vaccines like this may include pain at injection site, fever, fatigue, headache, muscle pain, chills, joint pain or swelling.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a healthy adult, not pregnant, and not breastfeeding.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, 29, 57
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, 29, 57 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Geometric mean titers of IgG and ELISA neutralizing antibodies
Percentage of participants with joint related symptoms, rash and unsolicited AEs
Percentage of participants with local injection site and systemic adverse events (AEs)
+4 more

Trial Design

8Treatment groups
Experimental Treatment
Placebo Group
Group I: Cohort 2 (next 60 subjects) PHV02 medium doseExperimental Treatment1 Intervention
Group II: Cohort 2 (next 60 subjects) PHV02 low doseExperimental Treatment1 Intervention
Group III: Cohort 2 (next 60 subjects) PHV02 high doseExperimental Treatment1 Intervention
Group IV: Cohort 1 (first 60 subjects) PHV02 medium doseExperimental Treatment1 Intervention
Group V: Cohort 1 (first 60 subjects) PHV02 low doseExperimental Treatment1 Intervention
Group VI: Cohort 1 (first 60 subjects) PHV02 high doseExperimental Treatment1 Intervention
Group VII: Cohort 2 (next 60 subjects) PlaceboPlacebo Group1 Intervention
Group VIII: Cohort 1 (first 60 subjects) PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PHV02
2022
Completed Phase 1
~60

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Public Health Vaccines LLCLead Sponsor
2 Previous Clinical Trials
96 Total Patients Enrolled
Coalition for Epidemic Preparedness InnovationsOTHER
35 Previous Clinical Trials
75,228 Total Patients Enrolled
Joan Fusco, PhDStudy ChairPublic Health Vaccines
1 Previous Clinical Trials
36 Total Patients Enrolled
~0 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top